

EKF Diagnostics Holdings plc
("EKF" or the "Company")

Total Voting Rights

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, in accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, announces that the total issued share capital of the Company consists of 454,930,564 Ordinary Shares of one penny each, of which 5,836,774 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 449,093,790.

The above figure of 449,093,790 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

EKF Diagnostics Holdings plc
Julian Baines, Executive Chair
Gavin Jones, Chief Executive Officer

www.ekfdiagnostics.com
via Walbrook PR

Singer Capital Markets (Nominated Adviser & Broker)
Phil Davies / Oliver Platts

Tel: +44 (0)20 7496 3000

Walbrook PR Limited
Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654



About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how

RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVREADSEDLNSEFA